AdvanceBio Peptide Plus - Peptide Characterization

Importance of the Topic

Accurate peptide characterization underpins biotherapeutic development and quality control by enabling identification of post‐translational modifications (PTMs) and synthetic peptide impurities. Selecting suitable stationary phases and mobile phase additives is key to achieving reliable separation, sensitive detection, and robust quantitation in both LC‐UV and LC‐MS workflows.

Objectives and Overview of the Application Note

The primary aim is to present the design features and performance advantages of the Agilent AdvanceBio Peptide Plus column. This superficially porous, hybrid endcapped C18 phase with a positively charged surface on a Poroshell 120, 2.7 µm particle is evaluated for peptide PTM analysis, impurity profiling, and method transfer between UV and MS detection.

Methodology and Instrumentation

The AdvanceBio Peptide Plus column was tested under UHPLC conditions using 0.1% formic acid as the mobile phase additive. Key parameters included:

• Column dimensions: 2.1 × 150 mm, 2.7 µm Poroshell 120
• Temperature: 60 °C
• Gradient: optimized for 3–30% acetonitrile in formic acid
• Detection: LC‐UV and high‐sensitivity ESI‐MS

Instrumentation consisted of standard Agilent UHPLC systems coupled to single‐quadrupole and high‐resolution MS platforms.

Main Results and Discussion

AdvanceBio Peptide Plus demonstrated:

• Improved peak shape and enhanced MS sensitivity when using formic acid versus conventional C18.
• High loadability with preserved peak symmetry at sample loads exceeding typical peptide mapping conditions.
• Alternative selectivity that resolves critical PTM pairs, notably deamidated variants with ~1 Da mass difference, which are often coeluted on neutral C18 phases.
• Seamless method transfer between LC‐MS (for impurity identification) and LC‐UV (for routine quantitation) without extensive re‐optimization.

Benefits and Practical Applications

Key advantages include:

• Unified workflow for discovery and QC labs, reducing time and cost of method redevelopment.
• Enhanced detection of low‐abundance peptides and PTMs in biotherapeutic and synthetic peptide analysis.
• Flexibility to switch between UV and MS detection in a single method.

This column is particularly suited for deamidation analysis, high‐mass‐load separations, and synthetic peptide impurity profiling.

Future Trends and Applications

Emerging directions include integration of charged‐surface chemistries with high‐field asymmetric waveform ion mobility spectrometry (FAIMS) for deeper PTM coverage, expansion to microflow LC‐MS for higher sensitivity, and application in multiomics workflows combining peptide and glycan analyses. Adoption of formic acid mobile phases continues to grow as LC‐MS becomes standard in both R&D and QC environments.

Conclusion

The AdvanceBio Peptide Plus column offers robust, high‐resolution peptide separations with formic acid mobile phases, delivering improved sensitivity, alternative selectivity, and streamlined method transfer. These features support more efficient identification and quantitation of PTMs and peptide impurities across biopharmaceutical workflows.

Reference

Agilent Technologies. AdvanceBio Peptide Plus Peptide Characterization. October 2020. Document RA.5079050926.